NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has signed a deal to provide clinical biomarker services to Eisai subsidiary H3 Biomedicine to support its development of H3B-8800, a small molecule drug candidate for certain blood cancers.
Cancer Genetics said it will specifically use next-generation sequencing, RNA expression profiling, and other technologies to provide biomarker-driven insights related to target engagement and patient response in a multi-center Phase I clinical trial of H3B-8800.
"We are very pleased to partner with Cancer Genetics and look forward to implementing their established oncology biomarker and molecular testing platforms," H3 Biomedicine Vice President Peter Smith said in a statement. "The important insights we may gain through this collaboration will ultimately help us advance our clinical program."
Also under the agreement, Cancer Genetics will provide biomarker discovery and development support for other early-stage drug candidates in H3's pipeline.
Additional terms were not disclosed.